Journal of Diagnostics Concepts & Practice >

2023 , Vol. 22 >Issue 05: 429 - 440

DOI: https://doi.org/10.16150/j.1671-2870.2023.05.003

Original articles

miR-1229-3p inhibits the malignant progression of colorectal cancer and serves as a potential biomarker

Expand
  • General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China

Received date: 2023-10-23

  Online published: 2024-03-15

Fold

Abstract

Objective: To investigate the role and clinical application of microRNA in the malignant progression of colorectal cancer (CRC). Methods: The transcriptome data of human colorectal cancer and adjacent tissues from TCGA database were analyzed to screen out the differentially expressed microRNAs (miRNAs), among which miR-1229-3p with the most significant difference was selected as the target miRNA, and furthermore the expression of miR-1229-3p was verified through GEO and Starbase databases. The biological functional characteristics of miR-1229-3p was analyzed through Bioinformatics. The miR-1229-3p overexpression cell line and miR-1229-3p knockdown cell line were constructed. The effect of miR-1229-3p on the proliferation, metastasis, and apoptosis of CRC cells was explored in vitro by CCK-8 experiment, cloning formation experiment, EdU experiment, transwell, and flow cytometry experiment. The effect of miR-1229-3p on the prolife-rative capacity of CRC in vivo was explored by nude mouse transplantation tumor experiment. The target genes of miR-1229-3p were screened out by DIANA, TargetScan, and miRDB databases. KEGG and GO were used to analyze the biological function of target genes. The expression of miR-1229-3p in plasma exosomes of 60 CRC patients and 60 healthy examiners obtained from Nanjing First Hospital were analyzed, and receiver operating characteristic curve (ROC) was used to distinguish its diagnostic efficacy for CRC patients. Results: The expression of miR-1229-3p was downregulated in CRC cells and tissues. Bioinformatics predicted a significant negative correlation between miR-1229-3p and tumor progression pathways, such as epithelial-mesenchymal transition and angiogenesis (R<0, P<0.05). In vitro and in vivo studies showed that after the overexpression of miR-1229-3p, the proliferation, migration and invasion of CRC cells were inhibited, and the potential target gene SETD7 was downregulated, while the apoptosis of CRC cells could be inhibited after downregulating miR-1229-3p. miR-1229-3p from plasma exosomes of CRC was downregulated, which could distinguish CRC patients from normal people. ROC curve showed that the optimal critical value of miR-1229-3p for diagnosing CRC was 0.586 8, and the area under the curve was 0.863 2 (P<0.01). Conclusions: The expression of miR-1229-3p is downregulated in CRC, and SETD7 is a potential target gene for miR-1229-3p. miR-1229-3p can inhibit the proliferation, migration and invasion of CRC cells, and promote apoptosis of CRC cells. miR-1229-3p can be served as a potential biomarker for CRC diagnosis.

Key words： Colorectal cancer; miR-1229-3p; SETD7; Exosomes; Biomarker

Cite this article

QIN Xiaodan, SUN Huiling, PAN Bei, PAN Yuqin, WANG Shukui . miR-1229-3p inhibits the malignant progression of colorectal cancer and serves as a potential biomarker[J]. Journal of Diagnostics Concepts & Practice, 2023 , 22(05) : 429 -440 . DOI: 10.16150/j.1671-2870.2023.05.003

References

[1] SIEGEL R L, MILLER K D, WAGLE N S, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1):17-48.
[2] 中华人民共和国国家卫生健康委员会. 中国结直肠癌诊疗规范(2023版)[J]. 中华消化外科杂志, 2023, 22(6):667-698.
  National Health Commission of the People′s Republic of China. Chinese protocol of diagnosis and treatment of colorectal cancer (2023 edition)[J]. Chin J Dig Surg, 2023, 22(6):667-698.
[3] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[4] ALLEMANI C, MATSUDA T, DI CARLO V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37?513?025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125):1023-1075.
[5] 张忠涛. 中国结直肠外科20年回顾与展望[J]. 中华消化外科杂志, 2022, 21(01):53-56.
  ZHANG Z T. Two-decade retrospect and prospect of colorectal surgery in China[J]. Chin J Dig Surg, 2022, 21(1):53-56.
[6] 杨盈, 孟文建, 王自强. 结直肠癌的综合治疗[J]. 中华消化外科杂志, 2022, 21(06):753-765.
  YANG Ying, MENG Wenjian, WANG Ziqiang. Comprehensive treatment of colorectal cancer[J]. Chin J Dig Surg, 2022, 21(06):753-765.
[7] HARRIS T J, MCCORMICK F. The molecular pathology of cancer[J]. Nat Rev Clin Oncol, 2010, 7(5):251-265.
[8] AMBROS V, BARTEL B, BARTEL D P, et al. A uniform system for microRNA annotation[J]. RNA, 2003, 9(3):277-279.
[9] POY M N, ELIASSON L, KRUTZFELDT J, et al. A pancreatic islet-specific microRNA regulates insulin secretion[J]. Nature, 2004, 432(7014):226-230.
[10] CALAME K. MicroRNA-155 function in B Cells[J]. Immunity, 2007, 27(6):825-827.
[11] GRECO S J, RAMESHWAR P. MicroRNAs regulate synthesis of the neurotransmitter substance P in human me-senchymal stem cell-derived neuronal cells[J]. Proc Natl Acad Sci U S A, 2007, 104(39):15484-15489.
[12] STEPONAITIENE R, KUPCINSKAS J, LANGNER C, et al. Epigenetic silencing of miR-137 is a frequent event in gastric carcinogenesis[J]. Mol Carcinog, 2016, 55(4):376-386.
[13] WANG F, YING H Q, HE B S, et al. Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway[J]. Oncotarget, 2015, 6(10):7899-7917.
[14] LIU R, GU J, JIANG P, et al. DNMT1-microRNA126 epigenetic circuit contributes to esophageal squamous cell carcinoma growth via ADAM9-EGFR-AKT signaling[J]. Clin Cancer Res, 2015, 21(4):854-863.
[15] LEE Y S, DUTTA A. MicroRNAs in cancer[J]. Annu Rev Pathol, 2009, 4:199-227.
[16] GILLIES J K, LORIMER I A. Regulation of p27Kip1 by miRNA 221/222 in glioblastoma[J]. Cell Cycle, 2007, 6(16):2005-2009.
[17] JOHNSON C D, ESQUELA-KERSCHER A, STEFANI G, et al. The let-7 microRNA represses cell proliferation pathways in human cells[J]. Cancer Res, 2007, 67(16):7713-7722.
[18] MOTT J L, KOBAYASHI S, BRONK S F, et al. mir-29 regulates Mcl-1 protein expression and apoptosis[J]. Oncogene, 2007, 26(42):6133-6140.
[19] BOMMER G T, GERIN I, FENG Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes[J]. Curr Biol, 2007, 17(15):1298-1307.
[20] SCOTT G K, GOGA A, BHAUMIK D, et al. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b[J]. J Biol Chem, 2007, 282(2):1479-1486.
[21] KUMAR M S, LU J, MERCER K L, et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis[J]. Nat Genet, 2007, 39(5):673-677.
[22] JUNG G, HERNáNDEZ-ILLáN E, MOREIRA L, et al. Epigenetics of colorectal cancer: biomarker and therapeutic potential[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(2):111-130.
[23] FARHAN M, WANG H, GAUR U, et al. FOXO signaling pathways as therapeutic targets in cancer[J]. Int J Biol Sci, 2017, 13(7):815-827.
[24] OUDHOFF M J, BRAAM M J S, FREEMAN S A, et al. SETD7 controls intestinal regeneration and tumorigene-sis by regulating Wnt/β-Catenin and Hippo/YAP signa-ling[J]. Dev Cell, 2016, 37(1):47-57.
[25] DEWS M, HOMAYOUNI A, YU D, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster[J]. Nat Genet, 2006, 38(9):1060-1065.
[26] MERTENS-TALCOTT S U, CHINTHARLAPALLI S, LI X, et al. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells[J]. Cancer Res, 2007, 67(22):11001-110011.
[27] HOU Y, ZHANG Q, PANG W, et al. YTHDC1-mediated augmentation of miR-30d in repressing pancreatic tumorigenesis via attenuation of RUNX1-induced transcriptional activation of Warburg effect[J]. Cell Death Differ, 2021, 28(11):3105-3124.
[28] KONOSHENKO M Y, BRYZGUNOVA O E, LAKTIONOV P P. miRNAs and androgen deprivation therapy for prostate cancer[J]. Biochim Biophys Acta Rev Cancer, 2021, 1876(2):188625.
[29] HU X, CHEN Q, GUO H, et al. Identification of target PTEN-based miR-425 and miR-576 as potential diagnostic and immunotherapeutic biomarkers of colorectal cancer with liver metastasis[J]. Front Oncol, 2021, 11:657984.
[30] LONE W, BOUSKA A, SHARMA S, et al. Genome-wide miRNA expression profiling of molecular subgroups of peripheral T-cell lymphoma[J]. Clin Cancer Res, 2021, 27(21):6039-6053.
[31] KONISHI H, SATO H, TAKAHASHI K, et al. Tumor-progressive mechanisms mediating miRNA-protein interaction[J]. Int J Mol Sci, 2021, 22(22):12303.
[32] BUTKYT? S, ?IUPAS L, JAKUBAUSKIEN? E, et al. Splicing-dependent expression of microRNAs of mirtron origin in human digestive and excretory system cancer cells[J]. Clin Epigenetics, 2016, 8:33.
[33] NISHIBEPPU K, KOMATSU S, IMAMURA T, et al. Plasma microRNA profiles: identification of miR-1229-3p as a novel chemoresistant and prognostic biomarker in gastric cancer[J]. Sci Rep, 2020, 10(1):3161.
[34] ZHAO X, CUI L. A robust six-miRNA prognostic signature for head and neck squamous cell carcinoma[J]. J Cell Physiol, 2020, 235(11):8799-8811.
[35] ZHANG C, ZHANG Q, LI H, et al. miR-1229-3p as a prognostic predictor facilitates cell viability, migration, and invasion of hepatocellular carcinoma[J]. Horm Metab Res, 2021, 53(11):759-766.
[36] CAO L, WANG M, XU K. Research progress of role and mechanism of SETD7 in tumor occurrence and progression[J]. Zhongguo Fei Ai Za Zhi, 2023, 26(1):38-45.
Options
Outlines

/

〈 〉